We have a consortium, scChemRISC, that develops a system for predicting the toxicity of compounds using ES cells. In the development of antiviral drugs, many products have side effects in clinical trials, and conventional safety evaluations require a huge budget and time, but using this system, we offer a technology that can predict toxicity risk rapidly, accurately and inexpensively. With this technology, we believe that it is possible to examine the differences in the reactions using iPS cells with ACE2 gene polymorphism.